Elizabeth Rozek's most recent trade in Sagimet Biosciences Inc - Ordinary Shares - Class A was a trade of 10,545 Series A Common Stock done at an average price of $7.8 . Disclosure was reported to the exchange on July 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | Chief Legal & Admin. Officer | Sale of securities on an exchange or to another person at price $ 7.76 per share. | 20 Jul 2026 | 10,545 | 224,414 | - | 7.8 | 81,832 | Series A Common Stock |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | Chief Legal & Admin. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | Chief Legal & Admin. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 88,000 | 88,000 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | Chief Legal & Admin. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2026 | 44,000 | 234,959 | - | 0 | Series A Common Stock | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | Chief Legal & Admin. Officer | Sale of securities on an exchange or to another person at price $ 5.36 per share. | 10 Feb 2026 | 2,622 | 190,959 | - | 5.4 | 14,054 | Series A Common Stock |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | Chief Legal & Admin. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2025 | 13,367 | 13,367 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | Chief Legal & Admin. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2025 | 9,855 | 193,581 | - | 0 | Series A Common Stock | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 9.13 per share. | 21 Jul 2025 | 10,780 | 183,726 | - | 9.1 | 98,471 | Series A Common Stock |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 138,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,000 | 194,506 | - | 0 | Series A Common Stock | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 3.10 per share. | 19 Jul 2024 | 10,914 | 160,506 | - | 3.1 | 33,830 | Series A Common Stock |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 242,142 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc (Class A) | Elizabeth Rozek | General Counsel and CCO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 0 | - | - | Stock Option (Right to Buy) |